<DOC>
	<DOCNO>NCT00034918</DOCNO>
	<brief_summary>The purpose study assess efficacy ZD6474 patient metastatic breast cancer 2 dose level .</brief_summary>
	<brief_title>This Study Assess Efficacy Safety ZD6474 Subjects With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histological and/or cytological confirmation metastatic breast cancer refractory anthracycline , taxane , without capecitabine therapy ; WHO performance status 0 , 1 2 day registration ; Females , age &gt; = 18 year ; No Gastrointestinal pathology could affect bioavailability ZD6474 . Any evidence severe uncontrolled systemic disease include know case Hepatitis B C human immunodeficiency virus ( HIV ) . Significant cardiac event ( include symptomatic heart failure unstable angina ) within 3 month entry cardiac disease opinion investigator increase risk ventricular arrhythmia ; History clinically significant cardiac arrhythmia ( multifocal PVCs , bigeminy , trigeminy , ventricular tachycardia ) , symptomatic require treatment ( CTC grade 3 ) asymptomatic sustain ventricular tachycardia ; Chronic atrial fibrillation ; Previous history QT / QTc prolongation medication ; Congenital long QT syndrome ; Systemic anticancer therapy investigational agent within last 4 week ( 6 week nitrosoureas , mitomycin C , suramin ) ; Currently receive drug know significant 3A4 inhibitory ( ie , ketoconazole , itraconazole , troleandomycin , erythromycin , diltiazem , verapamil ) stimulatory ( ie , phenytoin , carbamazepine , barbiturate , rifampicin ) effect ; Currently receive therapeutic dos warfarin ( Coumadin ? )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>